Login to Your Account

Pharma: Other News To Note

Friday, March 9, 2012
• Shire plc, of Dublin, Ireland, said it received approval through the European decentralized procedure for an oral powder formulation of Fosrenol (lanthanum carbonate), a noncalcium, nonresin phosphate binder, for use in the control of hyperphosphatemia in chronic renal failure patients on hemodialysis or continuous ambulatory peritoneal dialysis.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription